AU2003271043A1 - Albumin-fused ciliary neurotrophic factor - Google Patents

Albumin-fused ciliary neurotrophic factor Download PDF

Info

Publication number
AU2003271043A1
AU2003271043A1 AU2003271043A AU2003271043A AU2003271043A1 AU 2003271043 A1 AU2003271043 A1 AU 2003271043A1 AU 2003271043 A AU2003271043 A AU 2003271043A AU 2003271043 A AU2003271043 A AU 2003271043A AU 2003271043 A1 AU2003271043 A1 AU 2003271043A1
Authority
AU
Australia
Prior art keywords
albumin
protein
fused
biologically active
axokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003271043A
Other languages
English (en)
Inventor
Hans-Peter Hauser
Mathias Jurs
Darrell Sleep
Thomas Weimer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes Biopharma DK AS
Original Assignee
Novozymes Biopharma DK AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes Biopharma DK AS filed Critical Novozymes Biopharma DK AS
Publication of AU2003271043A1 publication Critical patent/AU2003271043A1/en
Assigned to NOVOZYMES DELTA LIMITED reassignment NOVOZYMES DELTA LIMITED Request for Assignment Assignors: DELTA BIOTECHNOLOGY LIMITED
Assigned to NOVOZYMES BIOPHARMA UK LIMITED reassignment NOVOZYMES BIOPHARMA UK LIMITED Alteration of Name(s) of Applicant(s) under S113 Assignors: NOVOZYMES DELTA LIMITED
Assigned to NOVOZYMES BIOPHARMA DK A/S reassignment NOVOZYMES BIOPHARMA DK A/S Request for Assignment Assignors: NOVOZYMES BIOPHARMA UK LIMITED
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003271043A 2002-08-07 2003-08-06 Albumin-fused ciliary neurotrophic factor Abandoned AU2003271043A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40183302P 2002-08-07 2002-08-07
US60/401,833 2002-08-07
PCT/EP2003/008710 WO2004015113A2 (en) 2002-08-07 2003-08-06 Albumin-fused ciliary neurotrophic factor

Publications (1)

Publication Number Publication Date
AU2003271043A1 true AU2003271043A1 (en) 2004-02-25

Family

ID=31715745

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003271043A Abandoned AU2003271043A1 (en) 2002-08-07 2003-08-06 Albumin-fused ciliary neurotrophic factor

Country Status (6)

Country Link
EP (1) EP1529108A2 (enExample)
JP (2) JP2005534330A (enExample)
KR (1) KR20050065519A (enExample)
AU (1) AU2003271043A1 (enExample)
CA (1) CA2496002A1 (enExample)
WO (1) WO2004015113A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
US9057061B2 (en) 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
CN102462662A (zh) * 2010-08-16 2012-05-23 重庆富进生物医药有限公司 脂质体包裹重组人睫状神经营养因子

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
ES2286128T3 (es) * 2000-06-30 2007-12-01 Zymogenetics, Inc. Proteina zcyto21 tipo interferon.

Also Published As

Publication number Publication date
KR20050065519A (ko) 2005-06-29
WO2004015113A2 (en) 2004-02-19
JP2005534330A (ja) 2005-11-17
EP1529108A2 (en) 2005-05-11
CA2496002A1 (en) 2004-02-19
WO2004015113A3 (en) 2004-05-06
JP2010213707A (ja) 2010-09-30

Similar Documents

Publication Publication Date Title
US20190085043A1 (en) Fusion proteins for treating a metabolic syndrome
CN102197049B (zh) 胰岛淀粉样多肽衍生物
AU2017367173B2 (en) New compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists
KR102066987B1 (ko) 폴리펩티드
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
US20080293638A1 (en) Albumin-fused ciliary neurotrophic factor
KR20230169417A (ko) Gdf15 융합 단백질 및 이의 용도
AU2003200839A1 (en) Extended glucagon-like peptide-1 analogs
JP2016519130A (ja) 治療ペプチド
JP2016535087A (ja) 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
JP2000516579A (ja) 腸栄養性ｇｌｐ―２ペプチドのアンタゴニスト
Bulaj et al. Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities
JP7471824B2 (ja) 高血糖症の治療及び予防のためのペプチド
EP3285798A2 (en) Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose
WO2018112200A1 (en) Use of fibroblast growth factor 1 (fgf1)-vagus nerve targeting chimeric proteins to treat hyperglycemia
JP2010213707A (ja) アルブミン融合繊毛様神経栄養因子
Sannikova et al. Specific activity of recombinant modified human glucagon-like peptide 1
WO2026039340A1 (en) Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026039359A1 (en) Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026039341A1 (en) Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2025117857A2 (en) Adp-ribosylation factor compositions and methods of use thereof
CN122036914A (zh) 一种长效化胰淀素受体激动剂及其用途
JP2017532292A (ja) ミリストイル化レプチン関連ペプチド及びその使用

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: NOVOZYMES DELTA LIMITED

Free format text: FORMER NAME: DELTA BIOTECHNOLOGY LIMITED

PC1 Assignment before grant (sect. 113)

Owner name: NOVOZYMES BIOPHARMA DK A/S

Free format text: FORMER APPLICANT(S): NOVOZYMES BIOPHARMA UK LIMITED

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application